keyword
https://read.qxmd.com/read/38092013/dabrafenib-plus-trametinib-in-unselected-advanced-braf-v600-mut-melanoma-a-non-interventional-multicenter-prospective-trial
#1
JOURNAL ARTICLE
Erika Richtig, Van A Nguyen, Peter Koelblinger, Ingrid Wolf, Helmut Kehrer, Werner Saxinger, Julia M Ressler, Georg Weinlich, Damian Meyersburg, Christine Hafner, Elisabeth Jecel-Grill, Julian Kofler, Bernhard Lange-Asschenfeldt, Felix Weihsengruber, Klemens Rappersberger, Nina Svastics, Klaus Gasser, Arno Seeber, Franz Kratochvill, Sophie Nagler, Bernhard Mraz, Christoph Hoeller
OBJECTIVE: The efficacy of combined BRAF and MEK inhibition for BRAF V600-mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real-world efficacy, safety and tolerability of dabrafenib plus trametinib in Austrian patients with unresectable/metastatic melanoma. METHODS: This multicenter, open-label, non-interventional, post-approval, observational study investigated the effectiveness of dabrafenib plus trametinib prescribed in day-to-day clinical practice to patients (N = 79) with BRAF V600-mutant unresectable/metastatic melanoma with M1c disease (American Joint Committee on Cancer staging manual version 7), ECOG > 1, and elevated serum lactate dehydrogenase (LDH)...
December 13, 2023: Melanoma Research
https://read.qxmd.com/read/36877310/investigating-the-burden-of-cardiovascular-comorbidities-in-inpatient-non-melanoma-skin-cancer-outcomes
#2
JOURNAL ARTICLE
Shrey Patel, Daphne G Eckembrecher, Francelia J Eckembrecher, Jamie K Hu, Eran Gwillim, Keyvan Nouri
While cardiovascular comorbidities can affect the outcomes of a variety of conditions, to our knowledge, few studies have evaluated their impact on non-melanoma skin cancers (NMSC). We studied the National Inpatient Sample to evaluate the impact of cardiovascular comorbidities on NMSC hospitalizations. Our findings displayed higher cost of care (Beta 5053; SE 1150; P < 0.001), length of stay (Beta 1.8; SE 0.394; P < 0.001), and mortality (aOR 2.51; CI 1.49-4.21; P < 0...
March 6, 2023: Archives of Dermatological Research
https://read.qxmd.com/read/35353346/tumor-in-the-crossfire-inhibiting-tgf-%C3%AE-to-enhance-cancer-immunotherapy
#3
REVIEW
Nicholas P Tschernia, James L Gulley
Cancer immunotherapy using monoclonal antibodies targeting immune checkpoints has undoubtedly revolutionized the cancer treatment landscape in the last decade. Immune checkpoint inhibitors can elicit long-lasting, previously unheard-of responses in a number of tumor entities. Yet, even in such tumors as metastatic melanoma and non-small cell-lung cancer, in which immune checkpoint inhibition has become the first-line treatment of choice, only a minority of patients will benefit considerably from these treatments...
March 2022: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://read.qxmd.com/read/35036074/personalized-therapy-with-peptide-based-neoantigen-vaccine-evx-01-including-a-novel-adjuvant-caf%C3%A2-09b-in-patients-with-metastatic-melanoma
#4
JOURNAL ARTICLE
Sofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, Arianna Draghi, Marie Christine Wulff Westergaard, Signe Koggersbøl Skadborg, Nana Overgaard, Anders Bundgård Sørensen, Ida Svahn Rasmussen, Lars Vibe Andreasen, Christina Westmose Yde, Thomas Trolle, Christian Garde, Jens Friis-Nielsen, Nis Nørgaard, Dennis Christensen, Jens Vindahl Kringelum, Marco Donia, Sine Reker Hadrup, Inge Marie Svane
The majority of neoantigens arise from unique mutations that are not shared between individual patients, making neoantigen-directed immunotherapy a fully personalized treatment approach. Novel technical advances in next-generation sequencing of tumor samples and artificial intelligence (AI) allow fast and systematic prediction of tumor neoantigens. This study investigates feasibility, safety, immunity, and anti-tumor potential of the personalized peptide-based neoantigen vaccine, EVX-01, including the novel CD8+ T-cell inducing adjuvant, CAF®09b, in patients with metastatic melanoma (NTC03715985)...
2022: Oncoimmunology
https://read.qxmd.com/read/34795506/venous-thromboembolism-in-hospitalized-melanoma-patients-analysis-from-the-national-inpatient-sample-database
#5
JOURNAL ARTICLE
Hussam Alhasson, Kadhim Al-Banaa, Mohammad Abu-Tineh, Bassam Alhasson, Yu Zhao, Mohamed A Yassin
Introduction: The association between cancer and hyper-coagulability is well known. However, the association between melanoma and venous thromboembolism (VTE) has not been identified. Methods: We studied the national inpatient sample (NIS) which compromise 20% of US hospitalization to better characterize melanoma and VTE. We analyzed the data between 2010 and 2014 using ICD-9 codes. Results: Melanoma patients were grouped into presence/absence of VTE...
2021: International Journal of General Medicine
https://read.qxmd.com/read/34716862/synergistic-effect-of-metformin-and-vemurufenib-plx4032-as-a-molecular-targeted-therapy-in-anaplastic-thyroid-cancer-an-in-vitro-study
#6
JOURNAL ARTICLE
Latha Durai, Soundharya Ravindran, Krishnamurthy Arvind, Devarajan Karunagaran, Ramshankar Vijayalakshmi
BACKGROUND: Survival rate of patients affected with anaplastic thyroid carcinoma (ATC) is less than 5% with current treatment. In ATC, BRAFV600E mutation is the major mutation that results in the transformation of normal cells in to an undifferentiated cancer cells via aberrant molecular signaling mechanisms. Although vemurufenib is a selective oral drug for the BRAFV600E mutant kinase with a response rate of nearly 50% in metastatic melanoma, our study has showed resistance to this drug in ATC...
November 2021: Molecular Biology Reports
https://read.qxmd.com/read/34700831/the-impact-of-radiation-therapy-on-obstetric-complications-in-cancer-survivors
#7
JOURNAL ARTICLE
I Bar Orian, Z Symon, S Appel, E Landau- Nof, O Kaidar-Person, Y Lawrence
PURPOSE/OBJECTIVE(S): Long-term side effects of radiation therapy (RT) include fibrosis, poor wound healing and hormonal dysfunction. These may potentially deleteriously affect obstetric outcomes amongst female cancer survivors, but there is minimal data. We hypothesized that previous RT treatment would be associated with increased maternal and fetal complications. MATERIALS/METHODS: We utilized the Nationwide Inpatient Sample (NIS) Healthcare Cost and Utilization Project, containing discharge data from 1,050 hospitals in 44 states, a 20% stratified sample of hospitals in the US...
November 1, 2021: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/32572113/nationwide-patterns-of-hemorrhagic-stroke-among-patients-hospitalized-with-brain-metastases-influence-of-primary-cancer-diagnosis-and-anticoagulation
#8
JOURNAL ARTICLE
Victor Lee, Vikram Jairam, James B Yu, Henry S Park
Brain metastases can contribute to a decreased quality of life for patients with cancer, often leading to malaise, neurologic dysfunction, or death. Intracerebral hemorrhage (ICH) is an especially feared complication in patients with brain metastases given the potential for significant morbidity and mortality. We aim to characterize patients with cancer and brain metastases admitted to hospitals nationwide and identify factors associated with ICH. The 2016 Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) was queried for all patients with cancer hospitalized with a diagnosis of brain metastases...
June 22, 2020: Scientific Reports
https://read.qxmd.com/read/31787545/regional-incidence-of-and-reconstructive-management-patterns-in-melanoma-and-nonmelanoma-skin-cancer-of-the-head-and-neck-a-3-year-analysis-in-the-inpatient-setting
#9
JOURNAL ARTICLE
Sabine A Egeler, Anne Huang, Anna R Johnson, Ahmed Ibrahim, Alexandra Bucknor, Abbas Peymani, Marc A M Mureau, Samuel J Lin
INTRODUCTION: Currently, there is limited literature on reconstructive trends for inpatient head and neck skin cancer. Rather, studies have focused primarily on patients treated on an outpatient basis. To gain a better understanding of the effect that reconstructive correction of complex skin cancer defects has on the healthcare system, we examined the existing incidence and reconstructive trends of head and neck melanoma and nonmelanoma skin cancer (NMSC) in the inpatient setting. METHOD: We performed the analysis of the Healthcare Cost and Utilization Project Nationwide Inpatient Sample Database (NIS) for the years 2012-2014 of the United States (US)...
November 9, 2019: Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS
https://read.qxmd.com/read/26799322/annual-hospital-volume-of-high-dose-interleukin-2-and-inpatient-mortality-in-melanoma-and-renal-cell-carcinoma-patients
#10
JOURNAL ARTICLE
Kathan Mehta, Leonard Appleman, Hong Wang, Ahmad A Tarhini, Rahul A Parikh
BACKGROUND: Immunotherapy using high dose interleukin-2 (HD IL2) in patients with renal cell carcinoma (RCC) and melanoma is associated with severe toxicities. The association between annual hospital volume of HD IL2 and inpatient mortality is not well studied. In this study we aim to quantify the impact of annual hospital volume of HD IL2 on inpatient mortality using National Inpatient Sample (NIS) data. METHODS: We did a cross-sectional study using NIS, one of the largest inpatient datasets in United States, from 2003 to 2011...
2016: PloS One
https://read.qxmd.com/read/25842835/-comparative-analysis-of-activity-of-different-promoters-for-nis-gene-expression-in-melanoma-cells
#11
COMPARATIVE STUDY
A I Kuz'mich, E P Kopantsev, T V Vinogradova, E D Sverdlov
Development of targeted drug delivery system is key problem of cancer gene therapy. To ensure specific delivery of these therapeutic compounds to the tumor it is preferable for therapeutic gene expression to occur predominantly in cancer cells. Therefore, when testing drug in vivo, it is necessary to study distribution of therapeutic gene expression products in different tissues of the organism. Sodium iodide symporter (NIS) is attractive reporter because its tissue level is easily quantitatively detected by noninvasive imaging methods...
January 2014: Molekuliarnaia Biologiia
https://read.qxmd.com/read/24662667/detecting-near-the-injection-site-sentinel-nodes-in-head-and-neck-melanomas-with-a-high-resolution-portable-gamma-camera
#12
JOURNAL ARTICLE
Daan Hellingman, Linda J de Wit-van der Veen, W Martin C Klop, Renato A Valdés Olmos
BACKGROUND: In head/neck melanomas, near-the-injection-site sentinel nodes (NIS-SNs) may be missed on planar lymphoscintigraphy and/or SPECT/CT. The aim of the present study is to establish the performance of a portable gamma camera (PGC) to detect NIS-SNs in a simulation phantom set-up, and subsequently in head/neck melanoma patients scheduled for a SN procedure. METHODS: Five plastic Eppendorf tubes filled with technetium-99m-albumin nanocolloid were used to simulate 4 radiotracer deposit sites, as traditionally injected in melanoma patients, and 1 NIS-SN...
January 2015: Clinical Nuclear Medicine
https://read.qxmd.com/read/24075405/microdistribution-of-mc1r-targeted-polyplexes-in-murine-melanoma-tumor-tissue
#13
JOURNAL ARTICLE
Mikhail O Durymanov, Tatiana A Slastnikova, Alexey I Kuzmich, Yuri V Khramtsov, Alexey V Ulasov, Andrey A Rosenkranz, Sergey Y Egorov, Eugene D Sverdlov, Alexander S Sobolev
Targeted sodium-iodide symporter (NIS) gene transfer can be considered as a promising approach for diagnostics of specific types of cancer. For this purpose we used targeted polyplexes based on PEI-PEG-MC1SP block-copolymer containing MC1SP-peptide, a ligand specific for melanocortin receptor-1 (MC1R) overexpressed on melanoma cells. Targeted polyplexes demonstrated enhanced NIS gene transfer compared to non-targeted (lacking MC1SP) ones in vitro. Using dorsal skinfold chamber and intravital microscopy we evaluated accumulation and microdistribution of quantum dot-labeled polyplexes in tumor and normal subcutaneous tissues up to 4 h after intravenous injection...
December 2013: Biomaterials
https://read.qxmd.com/read/22359623/induction-of-sodium-iodide-symporter-nis-expression-and-radioiodine-uptake-in-non-thyroid-cancer-cells
#14
JOURNAL ARTICLE
Zhi Liu, Mingzhao Xing
BACKGROUND: This study was designed to explore the therapeutic potential of suppressing MAP kinase and PI3K/Akt pathways and histone deacetylase (HDAC) to induce the expression of sodium/iodide symporter (NIS) and radioiodine uptake in non-thyroid cancer cells. METHODS: We tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon carcinoma, breast carcinoma, and brain cancers...
2012: PloS One
https://read.qxmd.com/read/21697253/telomerase-driven-expression-of-the-sodium-iodide-symporter-nis-for-in-vivo-radioiodide-treatment-of-cancer-a-new-broad-spectrum-nis-mediated-antitumor-approach
#15
JOURNAL ARTICLE
Garcilaso Riesco-Eizaguirre, Antonio De la Vieja, Irene Rodríguez, Soledad Miranda, Pilar Martín-Duque, Georges Vassaux, Pilar Santisteban
CONTEXT: Telomerase promoters (hTERT and hTR) are useful for transcriptional targeting in gene therapy models of cancer. Telomerase-driven expression of the sodium iodide symporter (NIS) in tumor cells has been successfully used as a reporter gene in vivo using positron emission tomography (PET) imaging. OBJECTIVE: The aim of this study was to investigate the NIS-mediated therapeutic effect of telomerase promoters in a wide variety of human cancer cell lines. DESIGN AND METHODS: Promoter fragments from either hTERT or hTR were used to drive the expression of NIS in cell lines derived from melanoma (M14), breast (MDA-MB-231), colon (HT-29), lung (H460), ovarian (OVCAR-3), and thyroid (TPC-1) carcinomas...
September 2011: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/21037556/targeting-of-tumor-radioiodine-therapy-by-expression-of-the-sodium-iodide-symporter-under-control-of-the-survivin-promoter
#16
JOURNAL ARTICLE
R Huang, Z Zhao, X Ma, S Li, R Gong, A Kuang
To test the feasibility of using the survivin promoter to induce specific expression of sodium/iodide symporter (NIS) in cancer cell lines and tumors for targeted use of radionuclide therapy, a recombinant adenovirus, Ad-SUR-NIS, that expressed the NIS gene under control of the survivin promoter was constructed. Ad-SUR-NIS mediating iodide uptake and cytotoxicity was performed in vitro. Scintigraphic, biodistribution and radioiodine therapy studies were performed in vivo. PC-3 (prostate); HepG2 (hepatoma) and A375 (melanoma) cancer cells all exhibited perchlorate-sensitive iodide uptake after infection with Ad-SUR-NIS, approximately 50 times higher than that of negative control Ad-CMV-GFP-infected cells...
February 2011: Cancer Gene Therapy
https://read.qxmd.com/read/17986062/immunohistochemical-expression-of-matrix-metalloproteinase-2-and-9-in-melanocytic-nevi-is-altered-by-ultraviolet-b
#17
JOURNAL ARTICLE
Renato Marchiori Bakos, Lucio Bakos, Maria Isabel Albano Edelweiss, André Cartell, José Carlos Mariante, Nathália Costaguta Matas Soles Masiero
BACKGROUND: Ultraviolet B (UVB) radiation can cause morphological and biological alterations similar to those of melanoma in situ in irradiated melanocytic nevi. matrix metalloproteinase (MMP-2) and -9 appear to be involved with tumour invasion, the formation of metastases and neoangiogenesis in melanomas. The effects of UVB on the immunohistochemical expression of gelatinases in different cell types in melanocytic nevi have not been completely studied. PURPOSE: Evaluate the effects of UVB on the immunohistochemical expression of MMP-2 and -9 in different cell types in melanocytic nevi...
December 2007: Photodermatology, Photoimmunology & Photomedicine
https://read.qxmd.com/read/14735456/the-na-i-symporter-nis-imaging-and-therapeutic-applications
#18
REVIEW
Ekaterina Dadachova, Nancy Carrasco
The Na(+)/I(-) symporter (NIS) is the plasma membrane glycoprotein that mediates the active uptake of I(-) in the thyroid, ie, the crucial first step in thyroid hormone biosynthesis. NIS also mediates I(-) uptake in other tissues, such as salivary glands, gastric mucosa, and lactating (but not nonlactating) mammary gland. The ability of thyroid cancer cells to actively transport I(-) via NIS provides a unique and effective delivery system to detect and target these cells for destruction with therapeutic doses of radioiodide...
January 2004: Seminars in Nuclear Medicine
https://read.qxmd.com/read/12508688/discriminant-analysis-of-image-karyometric-variables-in-benign-and-malignant-melanocytic-skin-lesions
#19
JOURNAL ARTICLE
Zaklina Mijovic, Dragan Mihailovic
OBJECTIVE: To perform a quantitative analysis to identify which of 7 nuclear morphometry-related variables are of diagnostic value in distinguishing benign from malignant melanocytic skin lesions. STUDY DESIGN: At the Institute of Pathology, University of Nis, formalin-fixed, paraffin-embedded skin biopsies from 23 cases of benign nevi (18 intradermal and 5 junctional) and 25 cases of primary nodular malignant melanomas were retrieved. Specimens were routinely stained with hematoxylin and eosin and analyzed using a computer-assisted interactive image analysis system...
December 2002: Analytical and Quantitative Cytology and Histology
https://read.qxmd.com/read/12477251/a-transporter-gene-sodium-iodide-symporter-for-dual-purposes-in-gene-therapy-imaging-and-therapy
#20
REVIEW
Je-Yoel Cho
Radioiodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by a plasma membrane transporter, sodium iodide symporter (NIS), provides a first step mechanism for thyroid cancer detection by radioiodide injection and effective radioiodide treatment for patients with invasive, recurrent, and/or metastatic thyroid cancers after total thyroidectomy. NIS gene transfer to tumor cells may significantly and specifically enhance internal radioactive accumulation of tumors following radioiodide administration, and result in better tumor control...
December 2002: Current Gene Therapy
keyword
keyword
83651
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.